Biohaven And Yale University Announce Federal Jury Verdict In Their Favor In Trade Secret Misappropriation And Breach Of Contract Litigation Against Avilar Therapeutics And RA Capital
Biohaven Ltd BHVN
$13.50
▼ -2.32%
($-0.32)
🎢 High Beta
🗓️ Earnings Next Week
Open
$13.87
Prev Close
$13.82
Day Range
$13.25 – $13.94
52W Range
$7.48 – $18.57
Market Cap
$2.03B
Beta
2.99
EPS (TTM)
$-5.67
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NEW YORK STOCK EXCHANGE, INC. |
| Currency | USD |
| IPO Date | 2022-09-23 |
| Shares Out. | 150,560,000 |
| Website | biohaven.com/ ↗ |
| Phone | 12034040410 |
| Employees | 274 |
| Net Income | -$130.5M |
| Free Cash Flow | -$594.5M |
| Total Assets | $466.4M |
| Total Liabilities | $336.9M |
| Equity | $129.5M |
About Biohaven Ltd
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Biohaven Ltd is a publicly traded company under the ticker symbol BHVN on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
25 analysts (2026-07-01)